List of Excipients in Branded Drug PROGLYCEM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	PROGLYCEM	diazoxide	0575-6200	ALCOHOL
Teva Pharmaceuticals USA Inc	PROGLYCEM	diazoxide	0575-6200	CARBOXYMETHYLCELLULOSE SODIUM
Teva Pharmaceuticals USA Inc	PROGLYCEM	diazoxide	0575-6200	HYDROCHLORIC ACID
Teva Pharmaceuticals USA Inc	PROGLYCEM	diazoxide	0575-6200	MAGNESIUM ALUMINUM SILICATE

PROGLYCEM Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

PROGLYCEM is an oral diazoxide product used to control hypoglycemia caused by hyperinsulinism and other conditions involving excessive insulin release. Its commercial opportunity is concentrated in formulation performance rather than active-ingredient exclusivity. Diazoxide is an old, non-biologic active ingredient with limited patent barriers, while the product’s value depends on reliable pediatric dosing, palatability, suspension uniformity, supply continuity, and access to suitable dosage forms.

The strongest excipient opportunities are:

1. Improved pediatric taste masking.
2. A lower-sugar or sugar-free oral suspension.
3. A preservative-reduced or preservative-free multidose formulation.
4. More robust suspension technology with reduced settling.
5. Unit-dose, ready-to-administer packaging.
6. Compounding and hospital-use presentations.
7. Alternative solid-dose formats for patients who cannot use the existing capsule or suspension.

What is PROGLYCEM and how is it used?

PROGLYCEM contains diazoxide, a potassium-channel opener that suppresses pancreatic insulin secretion. It is used primarily for hypoglycemia associated with hyperinsulinism, including congenital hyperinsulinism and selected non-insulinoma conditions.

Product characteristic	PROGLYCEM profile
Active ingredient	Diazoxide
Primary dosage forms	Oral suspension and capsules
Suspension strength	50 mg/mL
Therapeutic area	Hyperinsulinemic hypoglycemia
Main patient segment	Infants, children, and adults requiring chronic oral treatment
Administration challenge	Weight-based dosing and frequent dose adjustment
Key formulation issue	Accurate dosing and acceptable oral tolerability
Regulatory pathway	FDA-approved prescription drug
Product type	Small-molecule drug, not a biologic
Biosimilar exposure	None

The pediatric population creates a greater formulation burden than the capsule product suggests. Doses are commonly calculated by body weight, and treatment may begin in neonates or young children who cannot swallow capsules. The liquid formulation therefore has greater practical importance than its dosage-form designation implies.

What excipients are used in PROGLYCEM?

Public product labeling identifies the PROGLYCEM oral suspension as an aqueous formulation containing excipients used for sweetness, viscosity, preservation, solubilization, and physical stability. The capsule formulation uses conventional solid-dose excipients.

The oral suspension’s publicly listed excipient categories include:

Excipient function	Representative excipient disclosed in product information	Commercial purpose
Sweetening and bulk	Sorbitol	Improves mouthfeel and reduces reliance on sucrose
Cosolvent	Propylene glycol	Supports solubilization and formulation processing
Surfactant	Polysorbate 80	Supports wetting and dispersion
Preservative	Sodium benzoate	Controls microbial growth in the multidose liquid
High-intensity sweetener	Sodium saccharin	Improves palatability
Vehicle	Purified water	Continuous liquid phase
pH adjustment	Acid or base used as needed	Supports chemical and microbiological stability

The capsule product uses standard excipients associated with immediate-release solid oral dosage forms, including diluents, disintegrants, lubricants, and flow aids. Exact composition should be confirmed against the current approved labeling and supplier-specific product records before development or freedom-to-operate work. FDA’s Inactive Ingredient Database is relevant for precedent analysis, but it does not establish that a proposed formulation is clinically, commercially, or regulatory equivalent to PROGLYCEM. [1,2]

What formulation problems create opportunities around PROGLYCEM?

The principal weaknesses are practical rather than pharmacological.

Taste and oral acceptance

Diazoxide has an unpleasant taste profile. The current liquid product uses sweeteners, but sweetness alone does not eliminate bitterness or lingering aftertaste. Children may reject the product, spit out doses, or require administration through a feeding tube.

A reformulation opportunity exists in:

• Ion-exchange resin complexes.
• Polymer-based taste-masking coatings.
• Lipid or multiparticulate suspensions.
• Cyclodextrin or other complexation approaches.
• Flavored, pH-optimized aqueous systems.
• Small-volume concentrated liquids.
• Orodispersible or dispersible solid formats.

Taste masking must not delay diazoxide release in the stomach or create an excessive dose-volume burden. The target profile is a low-volume formulation that can be administered directly or through enteral feeding equipment.

Suspension uniformity

A 50 mg/mL suspension requires reliable redispersion after storage. Settling, caking, poor shake recovery, or dose nonuniformity can create clinically important underdosing or overdosing, particularly when caregivers administer small volumes with oral syringes.

Excipient and process opportunities include:

• Controlled flocculation.
• Structured vehicles.
• Cellulose-based suspending agents.
• Xanthan gum or similar rheology modifiers.
• Particle-size reduction.
• Narrow particle-size distribution.
• Wetting-agent optimization.
• Syringe-compatible viscosity control.

The development target should be measurable: uniform dose delivery at the beginning, middle, and end of the bottle after defined storage and handling conditions. A formulation that is easier to resuspend has direct value for pediatric adherence and medication safety.

Sugar and gastrointestinal tolerability

Sorbitol may improve sweetness and mouthfeel, but polyol exposure can contribute to gastrointestinal discomfort or diarrhea, depending on dose and patient sensitivity. This is relevant in infants and patients receiving multiple liquid medicines.

Potential alternatives include:

• Lower-sorbitol formulations.
• Sucrose-free systems using combinations of sucralose, acesulfame potassium, or other approved sweeteners.
• Reduced-polyol formulations.
• Highly concentrated liquids that reduce total excipient exposure.
• Powder-for-reconstitution products.

A lower-sorbitol product could have a commercial advantage if it preserves palatability while reducing gastrointestinal burden. Any such product would require comparative stability, preservative, and taste data.

Preservative exposure

Multidose aqueous products generally require antimicrobial protection unless packaged in a validated preservative-free delivery system. Sodium benzoate is used in the current oral suspension according to public product information. Preservative-reduced or preservative-free approaches could target neonates, medically fragile children, and institutions seeking lower excipient exposure.

Commercially viable options include:

• Unit-dose oral syringes.
• Blow-fill-seal packaging.
• Metered-dose dispensing systems.
• Smaller bottles with shorter in-use periods.
• A dry powder for reconstitution.
• A validated preservative-free suspension with sterile or low-bioburden manufacturing.

A preservative-free claim would require substantial microbiological and in-use testing. It is not achieved merely by removing sodium benzoate.

What PROGLYCEM formulations could be protected by patents?

A new patent estate would most plausibly attach to formulation and delivery claims, not to diazoxide itself.

Potential formulation claims

A sponsor could seek protection for:

• A diazoxide suspension with a defined particle-size range.
• A specific suspending-agent and surfactant combination.
• Improved redispersion after prolonged storage.
• A formulation with reduced settling or no hard cake.
• A low-sorbitol or sorbitol-free composition.
• A preservative-free multidose system.
• A taste-masked diazoxide particle.
• A defined pH range linked to stability.
• A high-concentration formulation with reduced administration volume.
• A formulation compatible with enteral feeding tubes.

The strongest claims would connect composition to a measurable performance result, such as dose uniformity, dissolution, redispersion time, microbial control, or stability.

Potential device and packaging claims

Commercial protection could also cover:

• Unit-dose prefilled oral syringes.
• A bottle-and-adapter system that limits dosing error.
• A shake-and-dose container.
• A feeding-tube-compatible closure.
• A packaging system that reduces sedimentation during storage.
• An administration device calibrated for weight-based dosing.

Device claims would not necessarily block a conventional generic suspension, but they could create differentiation in hospital and pediatric specialty channels.

Method-of-use claims

Method-of-use protection may be possible for narrow clinical applications, dosing regimens, or patient populations. Broad claims to treating hypoglycemia with diazoxide are vulnerable because the active ingredient and therapeutic use are long established.

Potentially differentiated areas include:

• Weight-based titration protocols.
• Use in a defined genetic subtype of congenital hyperinsulinism.
• A specific neonatal dosing regimen.
• Combination use with nutritional or endocrine interventions.
• A regimen designed to reduce adverse effects while maintaining glycemic control.

Method-of-use claims would face substantial prior-art and obviousness risk. Their commercial value would depend on whether prescribers follow the patented regimen and whether labeling supports the claimed use.

When does PROGLYCEM lose exclusivity?

PROGLYCEM’s active ingredient is not protected by a modern composition-of-matter patent. Diazoxide was approved decades ago, and the commercial product does not have the exclusivity profile of a recently launched small molecule.

Exclusivity category	PROGLYCEM assessment
New chemical entity exclusivity	Expired
Composition-of-matter patent	No meaningful current barrier expected for diazoxide
Orphan-drug exclusivity	Not a reliable current barrier for the established product
Pediatric exclusivity	Any historical period would have expired
Formulation exclusivity	Depends on separately listed patents, if any
Method-of-use exclusivity	Narrow and claim-specific
Biosimilar exclusivity	Not applicable
Generic entry pathway	ANDA, subject to FDA requirements and Orange Book-listed patents

The relevant commercial question is therefore not when the active ingredient loses exclusivity. It already operates in a mature exclusivity environment. The question is whether a manufacturer can build a differentiated, FDA-compliant formulation with enough clinical or operational value to sustain pricing.

What is the Orange Book status of PROGLYCEM?

The Orange Book is the primary source for FDA-listed patents and therapeutic-equivalence information for approved small-molecule drug products. A prospective generic sponsor would review the current PROGLYCEM listing for:

• Active product strength.
• Dosage form.
• Reference listed drug status.
• Therapeutic-equivalence codes.
• Listed patents.
• Patent-use codes.
• Exclusivity entries.
• Availability of an approved ANDA.

For an old diazoxide product, the principal entry barrier is likely product development and regulatory execution rather than an active patent blocking the reference product. A sponsor must still assess any current formulation or method-of-use listing before filing.

How would a Paragraph IV challenge affect PROGLYCEM?

A Paragraph IV certification could challenge an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or would not be infringed by the proposed generic. The commercial consequences depend on the patent’s expiration date, claim scope, litigation response, and whether the ANDA product uses the same or a different formulation.

If no relevant unexpired patent is listed, the generic sponsor may use a Paragraph III certification or a certification pathway appropriate to the listed patent record. A Paragraph IV strategy is most relevant where a later formulation patent covers the suspension, delivery system, or method of use.

For a new excipient-based product, patent risk would move in the opposite direction: the reformulator could seek composition and performance claims that create a barrier against copycat liquid products.

How strong is the PROGLYCEM patent estate?

The underlying diazoxide patent estate is weak from a modern product-licensing perspective because the active ingredient is old and genericized. A new formulation estate could be materially stronger if it contains narrow but defensible claims supported by comparative data.

Patent asset	Likely strength	Commercial relevance
Diazoxide composition claims	Low	Limited or expired protection
Broad treatment-of-hypoglycemia claims	Low	Extensive prior art
Specific pediatric dosing regimen	Low to moderate	Depends on clinical support
Taste-masked particle technology	Moderate	Useful if difficult to design around
Suspension stability composition	Moderate	Stronger with defined performance data
Preservative-free packaging	Moderate	May support product differentiation
Prefilled oral-syringe system	Moderate	Protects convenience and dosing control
Enteral-tube-compatible formulation	Moderate	Relevant to pediatric and hospital use
Manufacturing process claims	Moderate	Strongest when process materially improves quality

A formulation patent should avoid merely claiming a list of familiar excipients. Such claims are vulnerable if the combination would have been predictable to a skilled formulator. The stronger strategy is to claim a specific composition tied to unexpected stability, taste, redispersion, dose uniformity, or administration performance.

What commercial opportunities exist for PROGLYCEM reformulation?

Pediatric specialty product

The highest-value opportunity is a pediatric formulation designed around caregiver use. A product could combine:

• Low administration volume.
• Improved flavor.
• Oral-syringe dosing.
• Reliable redispersion.
• Reduced excipient burden.
• Clear weight-based dosing instructions.
• Feeding-tube compatibility.

Congenital hyperinsulinism is a specialty condition with a concentrated prescriber base. A manufacturer does not need broad primary-care penetration to establish a defensible niche.

Unit-dose and hospital packaging

Hospitals and specialty pharmacies may value ready-to-administer presentations that reduce preparation and dosing errors. Unit-dose syringes could improve:

• Pharmacy workflow.
• Inpatient administration.
• Discharge medication reconciliation.
• Caregiver training.
• Dose traceability.
• Short-term stability after dispensing.

The drawback is higher packaging cost and the need to validate extractables, leachables, syringe compatibility, and dose accuracy.

Powder for reconstitution

A powder-for-reconstitution product could reduce preservative requirements and improve shipping stability. It may also allow smaller commercial inventory and longer unopened shelf life.

Its disadvantages include:

• Reconstitution errors.
• Variable final volume.
• Need for a suitable measuring or dispensing device.
• Potential settling after reconstitution.
• Added pharmacy and caregiver instructions.

This format is more attractive where supply-chain stability is a major issue than where rapid, routine home administration is the primary concern.

Improved solid dosage forms

A dispersible tablet, mini-tablet, or orally disintegrating product could target older children and adults. The product would need to address:

• Dose flexibility.
• Swallowability.
• Dose titration.
• Taste during disintegration.
• Compatibility with feeding tubes.
• Accurate splitting or dispersion.

A mini-tablet platform could be particularly useful for weight-based pediatric dosing, but it would require a dose-selection strategy that is as practical as the current liquid.

Compounding and shortage protection

Diazoxide liquid compounding may occur when commercial supply is unavailable, the required concentration differs, or a patient cannot tolerate the marketed formulation. A manufacturer could pursue a pharmacy-friendly concentrate or kit with validated reconstitution instructions.

The opportunity is commercially meaningful only if the product offers a clear advantage over pharmacy compounding, such as:

• Longer beyond-use stability.
• Lower preparation burden.
• Better microbial control.
• More consistent concentration.
• Lower total cost of preparation.

Which companies are challenging PROGLYCEM?

The relevant competitive group includes generic manufacturers and specialty pharmaceutical companies capable of developing oral diazoxide products. Competition may arise through:

• ANDA submissions for an equivalent oral suspension.
• Generic capsules.
• Authorized-generic arrangements.
• Specialty formulations for congenital hyperinsulinism.
• Compounded products.
• Hospital pharmacy preparations.

A generic capsule is a limited substitute for infants and young children. The most commercially relevant competitive threat is therefore an equivalent or improved oral suspension, not simply a capsule ANDA.

Public FDA databases, Orange Book records, ANDA approvals, FDA drug-shortage records, and company product portfolios should be reviewed for current applicants and commercial suppliers. [1,3,4]

What regulatory pathway applies to an improved PROGLYCEM formulation?

A competing oral suspension containing diazoxide would generally be evaluated through the ANDA pathway if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A materially different formulation may require a 505(b)(2) application, particularly where the sponsor relies partly on existing diazoxide safety and efficacy information but introduces a new dosage form, excipient system, or delivery technology.

Development approach	Likely pathway	Strategic use
Same strength, dosage form, and route	ANDA	Lowest development cost if equivalence is achievable
Different excipient system with same dosage form	ANDA or 505(b)(2), depending on differences	Reformulation and differentiation
New pediatric delivery platform	Often 505(b)(2)	Clinical and usability differentiation
New dosing regimen	505(b)(2) or supplemental pathway	Method-of-use positioning
New device-led presentation	Combination-product assessment may apply	Dosing and administration advantage

FDA excipient review will focus on safety at the intended dose, route, age group, concentration, and duration. Pediatric use is important because excipient acceptability cannot be inferred solely from adult exposure. FDA’s inactive-ingredient resources and product-specific guidance should be used during formulation selection. [2,5]

What manufacturing and intellectual-property barriers affect entry?

The manufacturing barriers are manageable but operationally important.

Manufacturing barriers

A sponsor must control:

• Diazoxide particle size and polymorphic behavior.
• Wetting and dispersion.
• Suspension viscosity.
• Redispersion after storage.
• Microbial limits.
• Preservative effectiveness.
• Filling accuracy.
• Oral-syringe dose delivery.
• Bottle and closure compatibility.
• Stability after opening.
• Shipping under temperature variation.

A 50 mg/mL suspension may also create scale-up risks. Laboratory mixing can produce a uniform suspension that does not translate directly to commercial equipment. Process claims tied to mixing order, shear, homogenization, or particle conditioning may provide useful protection if they produce a measurable product advantage.

Intellectual-property barriers

The main IP risks include:

• Later-filed formulation patents.
• Taste-masking patents covering the selected technology.
• Suspension-stabilization patents.
• Packaging and dispensing-device patents.
• Third-party excipient supplier rights.
• Manufacturing-process patents.
• Method-of-use patents covering pediatric regimens.

Freedom-to-operate analysis should distinguish between the right to make diazoxide and the right to use a particular excipient technology or device.

How does PROGLYCEM compare with a differentiated diazoxide product?

Attribute	Existing PROGLYCEM-type product	Differentiated reformulation
Active ingredient	Diazoxide	Diazoxide
Core value	Established clinical use	Administration and adherence improvement
Primary dosage form	Suspension and capsule	Low-volume liquid, unit dose, mini-tablet, or device-led format
Excipient strategy	Conventional sweetener, preservative, surfactant, and vehicle system	Taste masking, lower excipient burden, improved stability
Patent position	Weak at active-ingredient level	Potentially moderate formulation and device protection
Regulatory route	Existing approval	ANDA or 505(b)(2), depending on differences
Main buyer	Specialty pharmacy, hospitals, caregivers	Same channels plus pediatric specialty networks
Main risk	Generic substitution and supply constraints	Development cost and limited patient population
Main commercial advantage	Familiarity and availability	Better dosing, tolerability, and handling

Key Takeaways

• PROGLYCEM is a diazoxide product whose commercial value depends more on formulation execution than active-ingredient exclusivity.
• The strongest opportunity is an improved pediatric oral suspension with better taste, reliable redispersion, low dosing volume, and oral-syringe compatibility.
• Lower-sorbitol, preservative-reduced, and preservative-free products could differentiate in neonatal and specialty-care settings.
• A new formulation patent should claim measurable performance, not merely a conventional list of excipients.
• Generic competition is more likely to target the oral suspension than the capsule because the pediatric market depends on liquid dosing.
• An ANDA may be appropriate for an equivalent product; a materially differentiated formulation may fit the 505(b)(2) pathway.
• No biosimilar risk applies because diazoxide is a small molecule.
• Unit-dose packaging, feeding-tube compatibility, and pharmacy-ready presentations offer commercial opportunities beyond excipient substitution.
• The most defensible product strategy combines formulation IP, delivery-device protection, pediatric usability data, and reliable supply.

FAQs

Can a sugar-free PROGLYCEM formulation be commercially differentiated?

Yes. A sugar-free or lower-polyol product could address caregiver concerns about gastrointestinal tolerability and reduce excipient exposure. Its value would depend on preserved palatability, suspension stability, microbial control, and dose uniformity.

Would a taste-masked diazoxide suspension require new clinical trials?

Not necessarily. The regulatory burden depends on the extent of formulation and pharmacokinetic differences. An ANDA may be possible for an equivalent product, while a materially different taste-masked system may require a 505(b)(2) application and additional bridging data.

Is diazoxide suitable for an orally disintegrating tablet?

Potentially, but the product must accommodate weight-based dosing, taste during disintegration, dose titration, and pediatric administration. A mini-tablet or dispersible tablet may be more practical than a conventional orally disintegrating tablet.

Can packaging claims protect a competing PROGLYCEM product?

Yes. A dispensing system, prefilled syringe, bottle adapter, or feeding-tube delivery system may support patent claims if it has a novel structure or produces a measurable dosing or handling advantage.

What is the most attractive near-term commercial opportunity?

A ready-to-administer pediatric suspension in unit-dose oral syringes, with improved taste, low volume, validated tube compatibility, and reduced settling, is the clearest near-term opportunity. It targets the main practical weaknesses of a conventional multidose diazoxide suspension without requiring a new active ingredient.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugsatfda
2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. Food and Drug Administration. (n.d.). FDA drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
5. U.S. Food and Drug Administration. (2016). Nonclinical studies for the safety evaluation of pharmaceutical excipients. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-studies-safety-evaluation-pharmaceutical-excipients
6. DailyMed. (n.d.). PROGLYCEM- diazoxide suspension. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/